Pharma

IP trouble defers launch of Novo’s long-acting hemophilia therapy

Long-acting hemophilia therapy Esperoct has won FDA approval, but US patients will have to wait until next year to access it, in a blow for maker Novo Nordisk which is looking to stave off Roche’s recently launched rival therapy Hemlibra.

Hemophilia A, or classic hemophilia, is a genetic disorder caused by a missing or defective clotting protein called factor VIII that causes prolonged bleeding or internal bleeding. To manage symptoms, an intravenous injection comprising the clotting factor is usually administered.

Esperoct — which is designed for use every four days — was granted approval on Tuesday, but the launch (cue drumroll) is planned for next year due to some pesky IP issues. In a statement the Danish drugmaker said it will not be able to launch Esperoct before 2020 due to third-party IP agreements. A company spokesperson declined to provide more detail.

Esperoct’s price will be announced in connection with the launch, the spokesperson added.

Novo $NVO already sells a hemophilia therapy called Novoeight, which is typically used every other day or three times a week for prophylaxis. Approved in October 2013 by the FDA, patent issues pushed the drug’s launch until 2015.

Meanwhile, Roche’s Hemlibra — approved in 2017 and launched in 2018 — is pegged to attain blockbuster status. It can be self-administered subcutaneously, versus traditional intravenous infusions, and has multiple dosing options: weekly, fortnightly and monthly.

Shire (now a part of Takeda) is another significant player in hemophilia. The company made its foray into the hemophilia market with its $32 billion buyout of Baxalta in 2016.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->